Experienced in Myeloproliferative Neoplasms (MPN)

Sujiang X. Zhang

197 Ruijin 2nd Road, 
Shanghai, CN 
Experienced in Myeloproliferative Neoplasms (MPN)
197 Ruijin 2nd Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Sujiang Zhang practices in Shanghai, China. Zhang is rated as an Experienced expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). Their top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Polycythemia Vera, and Acute Lymphoblastic Leukemia (ALL).

Their clinical research consists of co-authoring 29 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Myeloproliferative Neoplasms (MPN).

Locations

197 Ruijin 2nd Road, Shanghai, 200025, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: October 28, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat
Study Phase: Phase 3
Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome
Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome
Enrollment Status: Withdrawn
Publish Date: August 16, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Arsenic Trioxide
Study Phase: Phase 3
View 1 Less Clinical Trial

29 Total Publications

Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study.
Incidence, mortality, and survival associated with acute leukaemia subtypes by age group in China: a population-based cancer registry analysis and cohort study.
Journal: The Lancet. Haematology
Published: May 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile